Antibe Therapeutics

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Antibe Therapeutics had revenue of €0 and net profit of -€13.24M

(EUR)	2023	YoY
Revenue	0	-
Gross profit	0	100.00%
Net profit	-13.24M	26.85%
EBITDA	-13.05M	28.20%

Fundamentals

Metric	Value
Market capitalization	€10.21M
Number of shares	53.01M
52-week high/low	€0.19 - €0.17
Dividends	No
Beta	0.58
P/E ratio	-0.80
PEG ratio	-0.05
P/B ratio	0.38
P/S ratio	0.00

Company profile

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.